Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study

被引：0

作者：

Naoto Katakami

Tomoya Mita

Hidenori Yoshii

Toshihiko Shiraiwa

Tetsuyuki Yasuda

Yosuke Okada

Yutaka Umayahara

Hideaki Kaneto

Takeshi Osonoi

Tsunehiko Yamamoto

Nobuichi Kuribayashi

Kazuhisa Maeda

Hiroki Yokoyama

Keisuke Kosugi

Kentaro Ohtoshi

Isao Hayashi

Satoru Sumitani

Mamiko Tsugawa

Makoto Ohashi

Hideki Taki

Tadashi Nakamura

Satoshi Kawashima

Yasunori Sato

Hirotaka Watada

Iichiro Shimomura

机构：

[1] Osaka University Graduate School of Medicine,Department of Metabolic Medicine

[2] Osaka University Graduate School of Medicine,Department of Metabolism and Atherosclerosis

[3] Juntendo University Graduate School of Medicine,Department of Metabolism and Endocrinology

[4] Juntendo Tokyo Koto Geriatric Medical Center,Department of Medicine, Diabetology and Endocrinology

[5] Shiraiwa Medical Clinic,Department of Endocrinology and Metabolism

[6] Osaka Police Hospital,First Department of Internal Medicine, School of Medicine

[7] University of Occupational and Environmental Health,Department of Diabetes and Endocrinology

[8] Japan,Department of Diabetes, Endocrinology and Metabolism

[9] Osaka General Medical Center,Department of Endocrinology and Metabolism

[10] Kawasaki Medical School,Center for Diabetes Mellitus

[11] Nakakinen Clinic,Diabetes Center

[12] Diabetes and Endocrinology,Department of Internal Medicine

[13] Kansai Rosai Hospital,Department of Global Clinical Research, Graduate School of Medicine

[14] Misaki Naika Clinic,undefined

[15] Kitasenri Maeda Clinic,undefined

[16] Jiyugaoka Medical Clinic,undefined

[17] Kosugi Medical Clinic,undefined

[18] Otoshi Medical Clinic,undefined

[19] Hayashi Clinic,undefined

[20] Center for Diabetes and Endocrinology,undefined

[21] Nissay Hospital,undefined

[22] Ikeda Municipal Hospital,undefined

[23] Osaka Rosai Hospital,undefined

[24] National Hospital Organization Osaka National Hospital,undefined

[25] Kawasaki Hospital,undefined

[26] Kanda Naika Clinic,undefined

[27] Chiba University,undefined

来源：

Diabetes Therapy | 2017年 / 8卷

关键词：

Atherosclerosis; Diabetes; Intima-media thickness; SGLT2 inhibitor; Tofogliflozin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：999 / 1013

页数：14

共 50 条

[1] Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
Katakami, Naoto
Mita, Tomoya
Yoshii, Hidenori
Shiraiwa, Toshihiko
Yasuda, Tetsuyuki
Okada, Yosuke
Umayahara, Yutaka
Kaneto, Hideaki
Osonoi, Takeshi
Yamamoto, Tsunehiko
Kuribayashi, Nobuichi
Maeda, Kazuhisa
Yokoyama, Hiroki
Kosugi, Keisuke
Ohtoshi, Kentaro
Hayashi, Isao
Sumitani, Satoru
Tsugawa, Mamiko
Ohashi, Makoto
Taki, Hideki
Nakamura, Tadashi
Kawashima, Satoshi
Sato, Yasunori
Watada, Hirotaka
Shimomura, Iichiro
[J]. DIABETES THERAPY, 2017, 8 (05) : 999 - 1013
[2] Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
Katakami, Naoto
Mita, Tomoya
Yoshii, Hidenori
Shiraiwa, Toshihiko
Yasuda, Tetsuyuki
Okada, Yosuke
Torimoto, Keiichi
Umayahara, Yutaka
Kaneto, Hideaki
Osonoi, Takeshi
Yamamoto, Tsunehiko
Kuribayashi, Nobuichi
Maeda, Kazuhisa
Yokoyama, Hiroki
Kosugi, Keisuke
Ohtoshi, Kentaro
Hayashi, Isao
Sumitani, Satoru
Tsugawa, Mamiko
Ryomoto, Kayoko
Taki, Hideki
Nakamura, Tadashi
Kawashima, Satoshi
Sato, Yasunori
Watada, Hirotaka
Shimomura, Iichiro
[J]. CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[3] Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
Naoto Katakami
Tomoya Mita
Hidenori Yoshii
Toshihiko Shiraiwa
Tetsuyuki Yasuda
Yosuke Okada
Keiichi Torimoto
Yutaka Umayahara
Hideaki Kaneto
Takeshi Osonoi
Tsunehiko Yamamoto
Nobuichi Kuribayashi
Kazuhisa Maeda
Hiroki Yokoyama
Keisuke Kosugi
Kentaro Ohtoshi
Isao Hayashi
Satoru Sumitani
Mamiko Tsugawa
Kayoko Ryomoto
Hideki Taki
Tadashi Nakamura
Satoshi Kawashima
Yasunori Sato
Hirotaka Watada
Iichiro Shimomura
[J]. Cardiovascular Diabetology, 19
[4] Protective Effects of DPP-4 Inhibitor and SGLT2 Inhibitor on Pancreatic β-Cell Function-Randomized, Parallel-Group, Multicenter, Open-Label Study (SECRETE-I)
Shimoda, Masashi
Katakura, Yukino
Iwamoto, Masahiro
Kimura, Yukiko
Anno, Takatoshi
Isobe, Hayato
Iwamoto, Yuichiro
Fushimi, Yoshiro
Sanada, Junpei
Obata, Atsushi
Kimura, Tomohiko
Kawasaki, Fumiko
Tatsumi, Fuminori
Nakanishi, Shuhei
Mune, Tomoatsu
Kaku, Kohei
Kaneto, Hideaki
[J]. DIABETES, 2023, 72
[5] Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Katakami, Naoto
Mita, Tomoya
Yoshii, Hidenori
Shiraiwa, Toshihiko
Yasuda, Tetsuyuki
Okada, Yosuke
Torimoto, Keiichi
Umayahara, Yutaka
Kaneto, Hideaki
Osonoi, Takeshi
Yamamoto, Tsunehiko
Kuribayashi, Nobuichi
Maeda, Kazuhisa
Yokoyama, Hiroki
Kosugi, Keisuke
Ohtoshi, Kentaro
Hayashi, Isao
Sumitani, Satoru
Tsugawa, Mamiko
Ryomoto, Kayoko
Taki, Hideki
Nakamura, Tadashi
Kawashima, Satoshi
Sato, Yasunori
Watada, Hirotaka
Shimomura, Iichiro
[J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
[6] Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami
Tomoya Mita
Hidenori Yoshii
Toshihiko Shiraiwa
Tetsuyuki Yasuda
Yosuke Okada
Keiichi Torimoto
Yutaka Umayahara
Hideaki Kaneto
Takeshi Osonoi
Tsunehiko Yamamoto
Nobuichi Kuribayashi
Kazuhisa Maeda
Hiroki Yokoyama
Keisuke Kosugi
Kentaro Ohtoshi
Isao Hayashi
Satoru Sumitani
Mamiko Tsugawa
Kayoko Ryomoto
Hideki Taki
Tadashi Nakamura
Satoshi Kawashima
Yasunori Sato
Hirotaka Watada
Iichiro Shimomura
[J]. Cardiovascular Diabetology, 20
[7] Effect of Tofogliflozin on Carotid Intima-Media Thickness in Patients with Type 2 Diabetes: Results from the Prospective, Randomized, Open-Label, Parallel-Group Comparative UTOPIA Trial
Katakami, Naoto
Mita, Tomoya
Watada, Hirotaka
Shimomura, Iichiro
[J]. DIABETES, 2020, 69
[8] An open-label, randomized, parallel-group comparative study of the efficacy of sorghum bicolor extract in preoperative anemia
Tayo, Adetokunbo O.
Dosunmu, Adedoyin O.
Akinola, Ireti O.
Adewunmi, Adeniyi
Oloyede, Olufemi A.
Akinbami, Akinsegun A.
Osikomaiya, Bodunrin I.
Makanjuola, Samira B. L.
[J]. NUTRITION, 2017, 33 : 113 - 117
[9] Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
Katakami, Naoto
Mita, Tomoya
Yoshii, Hidenori
Onuma, Tomio
Kaneto, Hideaki
Osonoi, Takeshi
Shiraiwa, Toshihiko
Kosugi, Keisuke
Umayahara, Yutaka
Yamamoto, Tsunehiko
Yokoyama, Hiroki
Kuribayashi, Nobuichi
Jinnouchi, Hideaki
Gosho, Masahiko
Watada, Hirotaka
Shimomura, Iichiro
[J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2013, 20 (12) : 893 - 902
[10] Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform DisorderA 12-Week Prospective, Open-Label, Randomized, Parallel-Group Trial
Changsu Han
Chi-Un Pae
Bun-Hee Lee
Young-Hoon Ko
Prakash S. Masand
Ashwin A. Patkar
Sook-Haeng Joe
In-Kwa Jung
[J]. Clinical Drug Investigation, 2008, 28 : 251 - 261

← 1 2 3 4 5 →